Changes of CD68, CD163, and PD-L1 tumor expression during high-dose-rate and pulsed-dose-rate brachytherapy for cervical cancer

Francés, Miguel Ángel Berenguer; Linares-Galiana, Isabel; Cortés, Rut Cañas; Borràs, Susanna Marín i; Miguélez, Cristina; Najjari, D.; Slocker, Andrea; Bellobi, Cinta; Santacana, Marı́a; Foix, Maria Pane; Alonso, M. Henar; Navarro-Martín, Arturo; Antón, Silvia Comas; Guedea, Ferrán

doi:10.1016/j.brachy.2019.09.009

Cited by 7 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, the latter has a tumor-promoting phenotype with immunosuppressive and angiogenic capabilities that suppress tumor immunity [ 15 , 17 , 23 , 24 ]. Our study showed that the expression levels of CD68 and CD163 increased with treatment progression, contrary to the findings of Berenguer et al [ 22 ]. These differences may be because of the disuniformity in pathological evaluation arising from variations in the biopsy site, insufficient specimen volume, or the small number of cases.…”

Section: Discussioncontrasting

confidence: 99%

“…Several studies have demonstrated that the expression levels of PD-L1 increase following RT, which aided in the interpretation of our findings; the expression levels of PD-L1 increased before the initiation of ICBT [ 10 , 22 ]. However, subsequently, the dynamics of PD-L1 expression levels differed depending on whether recurrence or metastasis occurred within 2 years.…”

Section: Discussionmentioning

confidence: 63%

See 1 more Smart Citation

Dynamics in the expression of programmed death ligand 1 and cluster of differentiation 163 in the tumor microenvironment of uterine cervical cancer: a single-center retrospective study

et al. 2023

View full text Add to dashboard Cite

Background Radiotherapy (RT) destroys cancer cells and activates the immune system while suppressing the immunity of tumor-associated tissues, including the tumor microenvironment (TME). However, to date, no anti-tumor therapeutic strategy that uses these immune mechanisms has been established. This study investigated changes in the immunity of the TME during standard radical RT for cervical cancer combined with external beam RT and brachytherapy and determined whether these changes affect prognosis. Methods Twenty-six patients who had completed radical RT for cervical cancer were categorized into the following two groups according to whether the cancer recurred and/or metastasized within 2 years after the start of treatment: treatment failure (n = 14) and treatment success (n = 12). We assessed the expression of programmed death 1, programmed death ligand 1 (PD-L1), cluster of differentiation (CD) 8, CD68, CD163, Forkhead box protein P3, and hypoxia-inducible factor-1α in the TME of cervical tissues collected periodically during treatment and evaluated the difference in expression rates of each marker between the success and failure groups and assessed its effect on prognosis. Results The expression levels of PD-L1 and CD163 in the TME in the treatment success group were lower than those in the treatment failure group at the midpoint during brachytherapy (p < 0.01 and p = 0.08, respectively), and the 2-year progression-free-survival (PFS) rate depended on the expression levels of PD-L1 and CD163 (p = 0.04 and p = 0.02, respectively). Conclusions The expression rates of CD163 and PD-L1 in the TME during brachytherapy were related to treatment response and the 2-year PFS. This study may increase our understanding of tumor-associated immunity in the TME and aid in the development of therapies targeting PD-L1 or M2 macrophages in the TME in conjunction with RT, especially brachytherapy, for cervical cancer patients.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionmentioning

confidence: 63%

Dynamics in the expression of programmed death ligand 1 and cluster of differentiation 163 in the tumor microenvironment of uterine cervical cancer: a single-center retrospective study

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Only the triplet of brachytherapy and anti-PD-1 and CD137 antibodies generated a response in a contralateral and therefore, non-irradiated tumor lesion, suggesting an abscopal regression [50]. In addition, pre-clinical data shows an elevated expression of PD-L1 in a time interval after high-dose brachytherapy, demonstrating immuno-modulatory effect of this treatment modality and suggesting the use of PD-1/PD-L1 checkpoint blockade [51]. In a clinical study, with the objective to assess effectiveness of diffusing alpha emitters radiation therapy (DaRT), a spontaneous regression of untreated distant lesions was observed in a patient with multiple SCC lesions after treatment of a single-lesion with DaRT and with no immuno-therapeutic agent.…”

Section: Combination Of Immunotherapy Agents and Radiotherapy/brachytherapymentioning

confidence: 91%

Radioimmunotherapy: future prospects from the perspective of brachytherapy

Fleischmann¹,

Glatzer²,

Rödel³

et al. 2021

jcb

View full text Add to dashboard Cite

In combination with radiotherapy, immunotherapy is becoming an increasingly used strategy in treating advanced, recurrent, or metastatic cancer. The evident impact of radiotherapy on local and systemic immune response is an indication of the synergistic effect of these two modalities. There is a strong rationale to combine radiotherapy and immunotherapy to enhance response rates and overcome resistances. Therefore, the combination of radio-and immunotherapy holds a variety of opportunities as well as challenges in treating primary cancer and is progressively tested in curative settings. Brachytherapy is also known as internal radiation therapy and only offers a local therapy option at first glance: due to tumor-specific antigens, released by a high local radiation dose, a systemic immune response could be plausible and eminent. Accordingly, brachytherapy could be an underestimated partner with immuno-therapeutic approaches in both curative and palliative settings, to generate local and systemic response. In this review, we summarized the potential benefit of a potential combination of brachytherapy and immuno-therapeutic approaches vs. the background of limited data.

show abstract

Stereotactic body radiation therapy in the treatment of cancer patients with oligometastatic disease: a real world study

et al. 2022

View full text Add to dashboard Cite

Changes of CD68, CD163, and PD-L1 tumor expression during high-dose-rate and pulsed-dose-rate brachytherapy for cervical cancer

Cited by 7 publications

References 28 publications

Dynamics in the expression of programmed death ligand 1 and cluster of differentiation 163 in the tumor microenvironment of uterine cervical cancer: a single-center retrospective study

Dynamics in the expression of programmed death ligand 1 and cluster of differentiation 163 in the tumor microenvironment of uterine cervical cancer: a single-center retrospective study

Radioimmunotherapy: future prospects from the perspective of brachytherapy

Stereotactic body radiation therapy in the treatment of cancer patients with oligometastatic disease: a real world study

Contact Info

Product

Resources

About